Sarepta Therapeutics (SRPT) Stock Is About To Soar

Published 03/21/2016, 12:20 PM
Updated 07/09/2023, 06:31 AM

Sarepta Therapeutics (NASDAQ:SRPT) is an incredibly strong stock in the biotechnology space. However, it seems as though the stock is going to get stronger, and it's going to happen soon. I'm not quite sure what's up their sleeve, but insider trading shows that something big is likely to happen as SRPT. Today, we'll talk about why it's important to watch insider trading, what we're seeing from SRPT, and what we can expect to see moving forward. So, let's get right to it...

Why It's Important To Watch Insider Trading

As investors, we really don't have very much information available to us. Sure, we can watch technical data and focus on the fundamental data we know, but the truth is, most fundamentals are outdated by the time we get to them. Nonetheless, there is one clue that often leads to big gains, or big declines. That clue is insider trading. The bottom line is that no one knows more about a publicly traded company than those on the inside. When they start to sell shares in the company for which they are insiders, we can expect to see declines. However, when they start to buy shares, we can expect that something big is just around the corner, and SRPT insiders are buying shares!

We're Seeing Quite A Bit Of Insider Activity In Sarepta Therapeutics

Over the past week or so, we've seen quite a bit of positive insider activity at SRPT. In fact, over this short period of time, three directors at the company have made the decision to purchase shares. Between the three insiders, a total of 154,500 shares were purchased. The prices on these shares ranged from $14.54 per share to $16.54 per share, bringing the total cost to the insiders to approximately $2.5 million. When one insider purchases shares, we expect to see something good happen. However, in the case of SRPT, three insiders started loading up on shares at the same time. While I'm not sure what they're seeing coming around the corner, there's got to be a reason these three insiders jumped in on $2.5 million in shares of the company.

What We Can Expect To See Moving Forward

As mentioned above, I'm in the dark just like you when it comes to what's coming. The truth is that I have no crystal ball, nor do I have any other way to look into the future. However, I do know that when we start to see big insider buys, those insiders are buying for a reason. In the case of SRPT, I don't see this any different. The insiders made educated decisions to purchase shares. Why? I have no idea, but they did!

With that said, I'm expecting to see something big from the company relatively soon. Maybe they've reached a big time medical breakthrough, maybe they are expecting to move forward with a new clinical study, maybe they just have great financial data to report. Nonteheless, something is coming; so, we need to be watching closely. This could open the door to incredible trading opportunities.

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.